Swiss biotech startup ALP Bio is developing an AI-powered platform that helps drug developers identify immune-related risks earlier in the development process. The platform combines human tonsil-derived immune models with AI-based protein modelling to predict how the immune system is likely to respond to therapeutic antibodies, supporting safer biologic medicines.